Veronique Ouellet

Summary

Country: Canada

Publications

  1. pmc Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
    Veronique Ouellet
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Canada
    BMC Cancer 8:346. 2008
  2. pmc Characterization of three new serous epithelial ovarian cancer cell lines
    Veronique Ouellet
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Canada
    BMC Cancer 8:152. 2008
  3. doi request reprint BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer
    Cécile Le Page
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Quebec, Canada
    Cancer Epidemiol Biomarkers Prev 17:913-20. 2008
  4. ncbi request reprint An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer
    Veronique Ouellet
    The Research Centre of the University of Montreal Teaching Hospital CR CHUM Montreal Cancer Institute, Montreal, Quebec, Canada
    Cancer 110:297-308. 2007
  5. ncbi request reprint Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer
    Veronique Ouellet
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Canada
    Int J Cancer 119:599-607. 2006
  6. ncbi request reprint From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer
    Cécile Le Page
    Centre de Recherche du Center Hospitalier de l Université de Montréal CR CHUM, Institut du Cancer de Montreal, Montreal, Quebec, Canada
    Int J Cancer 118:1750-8. 2006
  7. pmc Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer
    Marie Line Puiffe
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Quebec, Canada
    Neoplasia 9:820-9. 2007
  8. ncbi request reprint SET complex in serous epithelial ovarian cancer
    Veronique Ouellet
    Centre de recherche du centre hospitalier de l Université de Montréal CHUM, Institut du Cancer de Montreal, Montreal, Canada
    Int J Cancer 119:2119-26. 2006
  9. ncbi request reprint Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling
    Veronique Ouellet
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Canada
    Oncogene 24:4672-87. 2005
  10. pmc An essential role for Ran GTPase in epithelial ovarian cancer cell survival
    Véronique Barrès
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, 1560 Sherbrooke Est, Montreal H2L 4M1, Canada
    Mol Cancer 9:272. 2010

Collaborators

Detail Information

Publications19

  1. pmc Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
    Veronique Ouellet
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Canada
    BMC Cancer 8:346. 2008
    ..Although the molecular characteristics of serous BOV, LMP and low grade (LG) TOV tumors has been initiated, definitive immunohistochemical markers to distinguish between these tumor types have not been defined...
  2. pmc Characterization of three new serous epithelial ovarian cancer cell lines
    Veronique Ouellet
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Canada
    BMC Cancer 8:152. 2008
    ....
  3. doi request reprint BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer
    Cécile Le Page
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Quebec, Canada
    Cancer Epidemiol Biomarkers Prev 17:913-20. 2008
    ..05, log-rank test) and Cox univariate as well as in multivariate analyses with a higher hazard ratio than clinical variables, such as residual disease, age, stage, and grade...
  4. ncbi request reprint An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer
    Veronique Ouellet
    The Research Centre of the University of Montreal Teaching Hospital CR CHUM Montreal Cancer Institute, Montreal, Quebec, Canada
    Cancer 110:297-308. 2007
    ..Among them, the apoptosis-related candidate genes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), caspase 8 (CASP8), FLICE-inhibitory protein (FLIP), and cytochrome C (CYC) were identified...
  5. ncbi request reprint Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer
    Veronique Ouellet
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Canada
    Int J Cancer 119:599-607. 2006
    ..001, 0.03, respectively). The application of these biomarkers in both the initial diagnosis and prognostic attributes of patients with epithelial ovarian tumors should prove to be useful in patient management...
  6. ncbi request reprint From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer
    Cécile Le Page
    Centre de Recherche du Center Hospitalier de l Université de Montréal CR CHUM, Institut du Cancer de Montreal, Montreal, Quebec, Canada
    Int J Cancer 118:1750-8. 2006
    ..Prospective studies with a large cohort of susceptible ovarian cancer patients will be required to expand these findings...
  7. pmc Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer
    Marie Line Puiffe
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Quebec, Canada
    Neoplasia 9:820-9. 2007
    ..The data support the validity of the strategy to uncover molecular events that are associated with tumor cell behavior and highlight the impact of ascites on the cellular and molecular parameters of ovarian cancer...
  8. ncbi request reprint SET complex in serous epithelial ovarian cancer
    Veronique Ouellet
    Centre de recherche du centre hospitalier de l Université de Montréal CHUM, Institut du Cancer de Montreal, Montreal, Canada
    Int J Cancer 119:2119-26. 2006
    ..05). These findings suggest that a strategy that sums the activities of different partners within a pathway may be more appropriate in designing nomograms for patient stratification...
  9. ncbi request reprint Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling
    Veronique Ouellet
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Canada
    Oncogene 24:4672-87. 2005
    ..These results define signature patterns for gene expression of LMPs and TOVs and identify gene candidates that warrant further study to deepen our understanding of the biology of EOC...
  10. pmc An essential role for Ran GTPase in epithelial ovarian cancer cell survival
    Véronique Barrès
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, 1560 Sherbrooke Est, Montreal H2L 4M1, Canada
    Mol Cancer 9:272. 2010
    ..Ran is known to contribute to both nucleocytoplasmic transport and cell cycle progression, but its role in ovarian cancer is not well defined...
  11. doi request reprint Protease inhibitor SERPINA1 expression in epithelial ovarian cancer
    Karine Normandin
    Institut du Cancer de Montreal, Centre de recherche du centre hospitalier de l Université de Montréal CHUM, Montreal, Canada
    Clin Exp Metastasis 27:55-69. 2010
    ..SERPINA1 remains an interesting candidate since protein homeostasis, regulated by proteases and their inhibitors, should be studied holistically in order to assess their full impact in tumor progression...
  12. pmc Necdin, a p53-target gene, is an inhibitor of p53-mediated growth arrest
    Julie Lafontaine
    Centre de recherche du Centre Hospitalier de l Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
    PLoS ONE 7:e31916. 2012
    ..We propose that in some contexts, the constitutive expression of Necdin could contribute to cancer promotion by delaying appropriate p53 responses and potentially promote genomic instability...
  13. doi request reprint DNA damage signaling and apoptosis in preinvasive tubal lesions of ovarian carcinoma
    Gautier Chene
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Quebec, Canada Department of Gynecology, Hopital Femme Mere Enfant, Hospices Civils de Lyon, Bron, France Departments of Pathology, and Gynecology, Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
    Int J Gynecol Cancer 25:761-9. 2015
    ....
  14. pmc Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases
    Sébastien Tabariès
    Goodman Cancer Research Centre, McGill University, 1160 Pine Avenue West, Room 513, Montreal, QC, H3A 1A3, Canada
    Breast Cancer Res 17:45. 2015
    ..Distinct immune infiltrates can either impair the metastatic process or conversely, assist in the seeding, colonization and growth of disseminated cancer cells...
  15. ncbi request reprint Signature of a silent killer: expression profiling in epithelial ovarian cancer
    Cécile Le Page
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, 1560, rue Sherbrooke Est, Montreal, Quebec H2L 4M1, Canada
    Expert Rev Mol Diagn 4:157-67. 2004
    ....
  16. doi request reprint Biopsy-based Proteomic Assay Predicts Risk of Biochemical Recurrence after Radical Prostatectomy
    Fred Saad
    Centre Hospitalier de l Universite de Montreal CHUM, Montreal, QC, Canada Université de Montréal Endowed Chair in Prostate Cancer, Montreal, QC, Canada Centre de recherche du CHUM and Institut du cancer de Montréal, Montreal, QC, Canada Department of Surgery Electronic address
    J Urol . 2016
    ....
  17. pmc A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer
    Daniel Taussky
    Department of Radiation Oncology, Centre Hospitalier de l Universite de Montreal CHUM, Hopital Notre Dame, Montreal, QC, Canada
    Can Urol Assoc J 10:246-250. 2016
    ..We sought to compare the outcomes between radical prostatectomy (RP) and permanent seed prostate brachytherapy (PB) in patients with low- and low-intermediate-risk prostate cancer from a single tertiary care centre...
  18. pmc CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis
    Veronique Ouellet
    Goodman Cancer Research Centre, McGill University, 1160 Pine Avenue West, Room 513, Montreal, Quebec, Canada, H3A 1A3
    J Cell Commun Signal 6:73-85. 2012
    ..More recently, emerging evidence suggests that CCN3 may also influence the ability of metastatic cancers to colonize and grow in bone...
  19. pmc CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone
    Veronique Ouellet
    Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada
    Am J Pathol 178:2377-88. 2011
    ..Together, these results demonstrate that CCN3 regulates the differentiation of bone resident cells to create a resorptive environment that promotes the formation of osteolytic breast cancer metastases...